Kitron ASA
10.12.2025 08:51:40 CET | Globenewswire | Press release
Kitron receives EUR 55 million defence order
Kitron receives EUR 55 million defence order
(2025-12-10) Kitron has received an order with a value of EUR 55 million from a customer in the Defence/Aerospace market sector.
"This order is yet another example of the strong demand we have reported in the defence sector, and it confirms our agility and ability to rapidly scale," says Peter Nilsson, CEO of Kitron.
Deliveries are set to take place in 2026.
For further information, please contact:
Peter Nilsson, President and CEO, tel. +47 948 40 850
Hans Petter Thomassen, VP Nordics and North America tel. +47 91392360
Email: investorrelations@kitron.com
Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The group has operations located in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, Malaysia, China and the United States. Kitron has about 3 000 employees, and revenues were EUR 647 million in 2024.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock exchange announcement was published by Cathrin Nylander, CFO of Kitron ASA, at the time and date stated above in this announcement.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom